increased incidence of vascular and cardiovascular disease, diabetes, hyperkeratosis, and cancers of the skin, lung, liver, bladder, kidney, and colon (ATSDR 1999a; Byrd et al. 1996; Leonard and Lauwerys 1980) .
The primary route of toxicologic concern for exposure to both nickel and chromium is inhalation, principally in occupational settings, although environmental exposures can also occur as a result of anthropogenic sources (IARC 1991; Leikauf 2002; Williams and Sandler 2001) . It has been estimated that 1.5 million workers are exposed to nickel occupationally in the United States (IARC 1991) . Particulate nickel is emitted into the atmosphere during oil and coal combustion, metal refining, nickel-alloy manufacturing and grinding, battery manufacturing, municipal incineration, electroplating, and stainless steel manufacturing, as well as from cigarette smoke and motor vehicle emissions, resulting in environmental inhalation exposure (Barceloux 1999; Laden et al. 2000; NiPERA 1999) . Dermal exposure can occur through skin contact with soil, water, or metals, including stainless steel or coins containing nickel (ATSDR 1999b) and can result in allergic reactions. Occupational exposure to nickel via inhalation is associated with respiratory distress and lung and nasal cancer (ATSDR 1999b; Denkhaus and Salnikow 2002; Leikauf 2002) .
Chromium(VI) enters the air principally as a result of coal and oil combustion, steel production, stainless steel welding, and chemical manufacturing (ATSDR 1998; Barnhart 1997; IARC 1991) . Chromium exposure can also occur from cigarette smoke. Discharge from electroplating, leather tanning, textiles, and dye and pigment manufacturing can contaminate water sources. Occupational exposure to chromium(VI) through inhalation causes respiratory tract problems and lung cancer, whereas dermal contact can lead to allergic contact dermatitis and skin ulceration (Alcedo and Wetterhahn 1990; ATSDR 1998; Dayan and Paine 2001) .
Cadmium inhalation can occur occupationally during battery manufacturing, metal soldering, or welding, as well as environmentally from burning fossil fuels, municipal waste, or cigarettes, and is associated with respiratory damage and cancer. Exposure can also occur through consumption of food or water containing cadmium, leading to gastrointestinal problems and kidney and bone disease, as well as increased body burdens of cadmium, which has a half-life of greater than 20 years in humans (ATSDR 2002; Beyersmann and Hechtenberg 1997; Jarup et al. 1998) .
Identification of genes whose expression is specifically modified by toxic metal exposure would provide a better understanding of their mechanisms of action and allow development of sensitive and specific biomarkers of both exposure and susceptibility for use in both mechanistic laboratory and epidemiology studies. In the current work we used cDNA microarrays to compare the effects of the toxic metals arsenic, cadmium, chromium, and nickel on expression of 1,200 human genes in human bronchial BEAS-2B cells, as lung is a target for effects of all four of these metals. We also confirmed the expression of certain relevant genes at the protein level in both epithelial and vascular smooth muscle cell models.
Methods
Cell treatment and preparation. Human bronchial epithelial cells (BEAS-2B; ATCC, Rockville, MD) were grown to postconfluence in 75-cm 2 flasks (Corning Costar, Corning, NY) on a matrix of 0.01 mg/mL human fibronectin (Collaborative Biomedical Products, Bedford, MA), 0.03 mg/mL Vitrogen 100 (Collagen Biomaterials, Palo Alto, CA), and 0.01 mg/mL bovine serum albumin (Sigma Chemical Co., St. Louis, MO). The cultures were maintained in LHC-9 medium (Biofluids Inc., Rockville, MD) at 37ºC under an atmosphere of 5% CO 2 /95% air, and medium was changed 24 hr before treatment.
Primary cultures of porcine smooth muscle cells (pSMC) were grown from medial explants of porcine aortas, using established methods (Ross 1971) . Briefly, segments of thoracic aorta were cleaned of outer adventitia, opened longitudinally, and scraped to remove endothelial cells. Segments of the remaining intima and media were cut into 1-mm squares and allowed to adhere to scored plastic dishes. The squares were then cultured with complete Dulbecco's modified Eagle's medium (DMEM; Cellgro MediaTech Inc., Herndon, VA) containing 1 mmol/L glucose, 10% fetal bovine serum, and 1% penicillin/streptomycin under an atmosphere of 10% CO 2 /90% air. The explants were removed once cells began to grow out. The cells were harvested in trypsin/ EDTA and replated for continued subculturing or characterization by immunohistochemistry. All cultures stained greater than 99% positive for α-actin. The cells used in these experiments were from passage 3 or 4.
For both cell types, treatments were chosen that did not cause overt signs of toxicity or changes in cell survival or replication as measured by long-term colony-forming assays. The exception was the 50-µM arsenic treatment used for dose-response comparisons. In all other cases, the doses of metal are relevant to those to which humans could be exposed. For example, levels of nickel found in the lungs of autopsied U.S. subjects with no known occupational exposure to nickel range between 1.8 and 2.1 mg Ni/cm 2 of lung surface area (Edelman and Roggli 1989) . Nickel refinery workers had much higher levels of nickel in the lung (mean 15 mg Ni/cm 2 ) (IARC 1991) .
cDNA array analysis. One confluent flask of > 10 7 cells BEAS-2B cells per treatment group of control cells or cells exposed to 5 or 50 µM sodium arsenite, 3 µM cadmium chloride, 10 µM sodium dichromate (Aldrich, St. Louis, MO), 3 µg/cm 2 of cell culture flask nickel subsulfide (Sigma), or 1 µM mitomycin C (MMC) for 4 hr was washed and scraped in ice-cold phosphatebuffered saline. Cells were then centrifuged, and the cell pellet was snap frozen in liquid nitrogen. The expression of 1,200 genes was assessed by cDNA microarray analysis using Clontech nylon membranebased Human Broad Coverage 1.2 I arrays (Clontech Laboratories Inc., Palo Alto, CA). Densitometry was performed on the hybridized membranes using a phosphoimager and the data were analyzed using AtlasImage software (Clontech Laboratories). The presence of nine housekeeping genes per array allowed us to discard housekeeping genes that were induced or repressed by a particular treatment (typically one to two of nine included on the array). The expression of each gene was normalized to the average of the remaining housekeeping genes. The housekeeping genes included on the array were ubiquitin, phospholipase A2, hypoxanthine-guanine, phosphoribosyltransferase (HPRT), liver glyceraldehyde 3-phosphate dehydrogenase (GAPDH), brain-specific tubulin alpha 1 subunit (TUBA1), HLA class I histocompatibility antigen C-4 alpha subunit (HLAC), cytoplasmic beta-actin (ACTB), 23-kDa highly basic protein, 60S ribosomal protein L13A (RPL13A), and 40S ribosomal protein S9.
The normalized ratios (treated divided by control) and differences (treated minus control) in gene expression between treated and control samples were calculated for all genes. Microarray analyses were repeated using n = 7 independent cultures for the housekeeping genes as well as two untreated independent cultures for all 1,200 genes, and inter-array variability was estimated to be < 22%. Within a single array, the variability of housekeeping gene expression was estimated to be between 8.4 and 20.9%. The housekeeping genes were used to calculate thresholds for each treatment. Thresholds were determined using fold changes 2 standard deviations outside of the average housekeeping gene value. The following threshold values were assigned on the basis of the underlying distribution of the data: 5 µM arsenic: ratio 1.69, difference 4; 50 µM arsenic: ratio 2.0, difference 13; chromium, cadmium, nickel, and MMC: ratio 1.49, difference 4. In addition to setting a threshold for the ratios, the difference between the treated samples and the controls was used to examine genes with low expression levels in which a fold change would be less reliable (e.g., 400/200 units compared with 4/2 units).
Immunoblot. The effects of arsenic exposure on hypoxia inducible factor-1α (HIF-1α) or β-actin protein levels (used as a loading control) were determined by Western blotting using a polyclonal antibody to HIF-1α (Transduction Laboratories, Lexington, KY) or a monoclonal antibody to β-actin (Sigma). Immunoblotting was performed as described previously (Andrew et al. 2001; Barchowsky et al. 1997) .
Kinase expression assay. For the kinase expression assay, the medium of 1-day postconfluent BEAS-2B cells was changed 12-18 hr prior to addition of 5 µM potassium dichromate (Aldrich) and the cells were treated for a time course of 1, 4, and 24 hr. pSMC were grown to 80-90% confluence in 75-cm 2 flasks (Corning Costar), and the medium was changed to a serumfree DMEM containing 1 mg/mL bovine serum albumin 20 hr prior to the addition of sodium arsenite. Cells were treated with 2.5 µM As for 1, 4, and 12 hr. A dose-response experiment using 1, 2.5, and 10 µM As was performed at 24 hr. Following treatment, cells were rinsed with Tris-buffered saline containing protease inhibitors, as described previously. The cells were then prepared as described (Kinexus Bioinformatics Corp. 2001) . Briefly, the cells were lysed in 20 mM 3-(N-morpholino)propanesulfonic acid, pH 7.0; 2 mM EGTA; 5 mM EDTA; 30 mM sodium fluoride; 40 mM β-glycerophosphate, pH 7.2; 10 mM sodium pyrophosphate; 2 mM sodium orthovanadate; and 0.5 % Nonidet P-40, supplemented with protease inhibitors. The cell lysates were sonicated twice for 15 sec and centrifuged for 2 hr at 19,000 rpm at 4˚C. A protein assay was performed on the supernatant, and a cell lysate mixture was adjusted to a concentration of 1 µg/µL using a 4 × sample buffer (50% glycerol; 125 mM Tris-HCl, pH 6.8; 4% sodium dodecyl sulfate; 0.08% bromophenol blue; 5% β-mercaptoethanol). Samples were heated at 100˚C for 4 min. The samples were analyzed via the Kinetworks' Protein Kinase Screen 1.0, a multiplexed western blot service provided by Kinexus Bioinformatics Corp. (Vancouver, British Columbia, Canada) . Kinexus loaded equal amounts of protein, quantified the blots by densitometry, and analyzed them using their proprietary software.
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Results
BEAS-2B human lung bronchial epithelial cells were treated for 4 hr either with arsenic (as sodium arsenite, 5 or 50 µM), cadmium (as cadmium chloride, 3 µM), chromium (as sodium dichromate, 10 µM), nickel (as nickel subsulfide, 3 µg/cm 2 ), or the genotoxic cancer chemotherapy drug MMC (1 µM). cDNA array analysis with 1,200 human genes (Clontech 1.2; Clontech) was performed with each treatment. The selected threshold fold change for each treatment was outside the 1.49-to 2.0-fold range in expression seen in the housekeeping genes (average plus 2 standard deviations).
The genes listed in Figure 1 showed increased or decreased expression following each treatment (see "Materials and Methods" for details). This Boolean schematic representation lists the genes uniquely changed by each exposure within the appropriate shape, with overlapping regions (or underlining for arsenic) indicating genes that were modified by more than one treatment. To summarize the data, low-dose cadmium altered the expression of 25 genes; chromium, 44; nickel, 31; 5 µM arsenic, 110 ( Figure 2) ; 50 µM arsenic, 65; and MMC, 16 genes.
As shown in Figure 1 , although there was some overlap, overall each treatment modified expression of a largely unique set of genes. Only heat-shock protein 90A (HSP 90A) expression was modified by treatment with all four of the metals tested, and no gene's expression was modified by all five treatments. Several genes were differentially regulated in response to three metals: cadmium, chromium, and nickel. Specifically, these three metals induced expression of erythrocyte glucose transporter 1 (GLUT1) and decreased transcriptional activator (DB1), collagen type 4 (COL4A2), glutathione peroxidase (GSHPX1), hepatoma-derived growth factor (HDGF), and cytochrome P450 1B1 (CYP1B1) (Figure 1, overlapping region) . Interestingly, when two or more exposures affected expression of the same gene, the expression was usually altered in the same direction, that is, increased or decreased, with each exposure. The only exception was that treatment with the organic DNAdamaging agent MMC induced expression of early growth response protein 1 (hEGR1), whereas chromium, arsenic, and nickel all suppressed expression of this gene (Figure 1, black font) .
To explore the effects of dose on the gene expression profile, we exposed cells for 4 hr to two different doses of arsenic: 5 µM, which caused little or no cytotoxicity, or 50 µM, which was highly cytotoxic as determined by a colony-forming assay. Figure 1 . Gene expression profiles for cells treated with cadmium, chromium, nickel, or MMC. Relative expression of 1,200 genes was assessed in human bronchial BEAS-2B cells exposed for 4 hr to cadmium (10 µM Cd 2+ as cadmium chloride), chromium(VI) (10 µM Cr(VI) as sodium dichromate), nickel (3 µg/cm 2 Ni 2+ as nickel subsulfide), and mitomycin C (1.0 µM MMC) using cDNA microarray analysis. Genes with expression changes above a statistically derived threshold for an exposure (minimum 1.5-fold) are listed within each designated shape using the abbreviations defined in Table 1 . Font color indicates an increase (red) or decrease (blue) in expression relative to control. Black font indicates a gene whose expression was induced by one treatment but suppressed by another. Genes with modified expression following exposure to more than one metal are found in the relevant overlapping areas. Genes modified by arsenic in addition to chromium, cadmium, nickel, or MMC are underlined. 
Decreased expression Increased expression 50 µM As 5 µM As Of the 1,200 genes examined at both doses, only 16 of 158 affected genes were altered at both doses ( Figure 2 , overlapping region). All genes altered by 50 µM arsenic were increased in expression (red font) with the exception of monocyte chemotactic protein 1 precursor (MCP1) (blue font). In contrast, 5 µM arsenic increased (red font) or decreased (blue font) expression of genes in similar numbers. Interestingly, more total genes were affected by the lower dose than by the higher cytotoxic dose. As might be expected, at the higher dose, stress response and apoptotic genes predominated. Interestingly, most of these genes were unaffected at the lower dose. Western immunoblot and kinase expression assays were performed for certain genes to determine whether the altered gene expression seen in the microarray assays was paralleled by a change in protein expression. Immunoblots ( Figure 3 ) demonstrated increases in protein levels of the transcription factor HIF-1α, following exposure to arsenic for 4, 8, or 24 hr, which are consistent with the increased HIF-1α mRNA levels observed after 5-µM arsenic exposure (Figure 2 ). This level of arsenic exposure did not affect β-actin expression, which was used as a loading control.
Assays for kinase protein expression changes were performed on cells exposed to arsenic or chromium over a range of doses and time points in two separate cell types. The ratio of mRNA levels in exposed versus control cells (Figure 4 ) was compared with the ratio of protein levels observed in the kinase expression assay for each kinase (Figure 4 ). ERK3 gene and protein levels were increased at most arsenic doses and time points tested ( Figure 4A ), whereas RSK1, PKACα, and PKBα/akt1 all showed consistent decreases in expression following arsenic exposure in both assays ( Figure  4B-D) . Chromium exposure also decreased mRNA and protein levels of PKBα/akt1 ( Figure 4E ). Thus, for the genes and gene products examined, changes in mRNA expression were similar to changes in protein expression.
Discussion
Chronic exposure to the toxic metals arsenic, chromium, cadmium, and nickel has been associated with a wide variety of adverse health effects (ATSDR 1998 (ATSDR , 1999a (ATSDR ,1999b (ATSDR , 2002 . Previous studies of individual genes have demonstrated that these metals can each substantially alter gene expression in various cell and whole animal systems (Andrew and Barchowsky 2000; Hamilton and Wetterhahn 1989; Hamilton et al. 1998; Ihnat et al. 1997; McCaffrey et al. 1994) . The development of gene array technology has provided a means for examination of alterations in gene expression on a more global level. The current study describes profiles of early changes in gene and protein expression that (A) Confluent BEAS-2B cells were exposed to 2.5 µM arsenic for 4, 8, or 24 hr. Cells were harvested for total protein and Western blots were performed as described in "Materials and Methods," using antibodies to HIF-1α or the loading control β-actin. (B) The band density ratio of HIF-1α to β-actin density of bands shown in A. Data represent protein collected from independent experiments. Values are means SD; n = 3. 8-hr arsenic, **p < 0.001; 24-hr arsenic, ***p < 0.05 vs. control. PKBα in response to arsenic exposure were measured at both the gene level by cDNA array analysis and at the protein level by a kinase assay as described in "Materials and Methods." Data under the heading "Array" represent the normalized ratio of gene expression for arsenic-exposed cells compared with that of control, whereas data under the heading "Kinase expression assay" represent the ratio of protein levels for arsenicexposed smooth muscle cells compared with that of control. (E) This graph shows the ratio of changes in PKBα gene and protein expression after chromium treatment, as described above for arsenic. Treatment time is indicated on the graph below each bar, and bar shading designates the dose of arsenic or chromium, as shown in the legend. 
BSP1
Transforming growth factor-beta 3.50 2.44 U57456 signaling protein 1 (BSP1); mothers against dpp homolog (MAD); MADR1; MSMAD1
BTEB2
Basic transcription element-binding 2.26 2.59 D14520 protein 2 (BTEB2); GC-box binding protein 2
BTF2p44
Basic transcription factor 2 44-kDa 1.90 Z30094 subunit (BTF2p44)
CANP
Calpain 2 large (catalytic) subunit; 1.82 M23254 M-type calcium-activated neutral proteinase (CANP)
CAP2
Cytoplasmic antiproteinase 2 (CAP2); 2.00 L40377 protease inhibitor 8
CASP2
Caspase GABP-α GA-binding protein alpha subunit (GABP-2.33 D13316 alpha); transcription factor E4TF1-47; nuclear respiratory factor-2 alpha subunit
GADD153
Growth arrest and DNA-damage-inducible 10.35 S40706; protein 153 (GADD153); DNA-damage-S62138 inducible transcript 3 (DDIT3); C/EBP homologous protein (CHOP)
GADD45
Growth arrest and DNA-damage-inducible 2.60 13.88 M60974 protein (GADD45); DNA-damage-inducible transcript 1 (DDIT1)
GADD45β
Growth arrest and DNA-damage-inducible 3.23 AF078077 protein 45 beta (GADD45 beta)
GALNR1
Galanin receptor type 1 (GALNR1; GALR1) 2.78 L34339 GAP GAP-associated protein 2.00 U17032
GLUT1
Erythrocyte glucose transporter 1 (GLUT1) 1.86 1.64 1.93 K03195 GNBP Guanine nucleotide-binding protein 2.50 M36429 G-i/G-s/G-t beta subunit 2; transducin beta 2 subunit 2
GRRF1
Glucocorticoid receptor repression factor 1 2.00 M73077
GSHPX1
Glutathione peroxidase (GSHPX1; GPX1) 2.00 1.68 1.62 Y00483; M21304 GSR Glutathione reductase (GRase; GSR; GR) 1.60 X15722
H2TF1
Nuclear factor NF-kappa-B p100 subunit; 1.71 X61498 nuclear factor NF-kappa-B p52 subunit; H2TF1; oncogene lyt-10 
IL-10
Interleukin-10 precursor (IL-10); cytokine 1.54 M57627 synthesis inhibitory factor (CSIF)
IL-11
Interleukin-11 (IL-11); adipogenesis 13.33 M57765 inhibitory factor (AGIF)
IL-12B
Interleukin-12 beta subunit precursor 2.50 6.00 M65290 (IL-12B); cytotoxic lymphocyte maturation factor 40-kDa subunit (CLMF p40); NK cell stimulatory factor subunit 2 (NKSF2)
IL-1R2
Interleukin-1 receptor type II precursor 2.40 X59770 (IL-1R2); IL-1R-beta
IL-2
Interleukin-2 precursor (IL-2); T-cell 1.90 A14844 growth factor (TCGF)
IL2RA
Interleukin-2 receptor alpha subunit 1.74 X01057; precursor (IL-2 receptor alpha subunit; X01058; IL2RA); p55; TAC antigen; CD25 X01402
IL-5RA
Interleukin-5 receptor alpha subunit 2.66 M75914 precursor (IL-5R-alpha; IL5RA); CD125 antigen (Continued on next page) 
MAPKK3
Dual specificity mitogen-activated protein 2.78 L36719 kinase kinase 3 (MAP kinase kinase 3; MAPKK 3; MKK3); ERK activator kinase 3; MAPK/ERK kinase 3 (MEK3)
MCL-1
Induced myeloid leukemia cell 2.23 2.00 L08246 differentiation protein MCL-1
MCM2
MCM2 DNA replication licensing factor; 2.24 D21063 nuclear protein BM28; KIAA0030
MCM5
MCM5 DNA replication licensing factor; 1.72 X74795 CDC46 homolog
MCM7
MCM7 DNA replication licensing factor; 2.24 D55716 CDC47 homolog; p1.1-MCM3
MCP1
Monocyte chemotactic protein 1 precursor 2.21 7.00 2.33 M24545 (MCP1); monocyte chemotactic and activating factor (MCAF); monocyte secretory protein JE; monocyte chemoattractant protein 1; HC11; small inducible cytokine A2 (SCYA2)
MCT1
Monocarboxylate transporter 1 (MCT1) 3.50 L31801
MGMT 6-O-methylguanine-DNA methyltransferase 1.83 M29971 (MGMT); methylated-DNA-protein-cysteine methyltransferase
MIP2-α
Macrophage inflammatory protein 2 alpha 2.03 2.11 X53799 (MIP2-alpha); growth-regulated protein beta (GRO-beta) are observed in response to toxic metal exposure. These early changes may provide further insight into mechanisms underlying development of metal-induced diseases. These early gene and protein responses are also candidate biomarkers of metal exposure and/or effect that could potentially be used diagnostically in molecular and epidemiologic studies.
Results of the cDNA microarray experiments indicate that exposure to these toxic metals modifies expression of only a small subset of the 1,200 total genes examined (Figures 1 and 2) , which is consistent with the concept that these were low, relatively nontoxic doses that did not activate large numbers of nonspecific pathways of toxicity response (with the exception of 50 µM arsenic). Although there is some overlap in the genes modified between different metals, these data suggest that each metal modifies expression of a largely unique set of genes that may be characteristic of each treatment. Although this microarray does not contain all known metal-responsive genes, the results show metal-specific patterns of expression among the genes examined. No gene was modified by all five chemical treatments, and only HSP-90A was modified by all four metals. Only three to seven genes overlapped among any two treatments, and similarly, only a few genes were common to any three treatments. A similar unique pattern of gene expression has been observed in yeast exposed to equitoxic doses of several different alkylating agents (Jelinsky et al. 2000) as well as in rats treated with different classes of drugs (Hamadeh et al. 2002a (Hamadeh et al. , 2002b . Likewise, cadmium chloride, benzo[a]pyrene and trichloroethylene produced different patterns of gene expression in the livers of exposed mice (Bartosiewicz et al. 2001) .
In this study the genes that were altered commonly by more than one treatment were all changed in the same direction, that is, either increased or decreased expression. This supports the idea that these represent biologically relevant responses to these treatments. Cadmium, chromium, and nickel exposures all increased expression of GLUT1 and decreased levels of transcription activator DB1 (DB1), procollagen alpha 2(IV) subunit precursor (COL4A2), glutathione peroxidase (GSHPX1), hepatomaderived growth factor (HDGF), and cytochrome P450 1B1 (CYP1B1). Despite the known ability of Cr(VI) and MMC to cause both monoadducts and cross-links in DNA, only 7 genes were modified in common by both of these agents. A previous 148-gene microarray experiment showed changes in expression of 12 genes in the liver following cadmium exposure (Bartosiewicz et al. 2001) . Organ-specific effects as well as differences in the particular genes included in each microarray may explain the lack of overlap between these two studies. Previous studies indicate that 4-hr nickel exposure stabilizes HIF-1α protein resulting in transcriptional activation of hypoxia-inducible genes (Andrew et al. 2001; Salnikow et al. 2000) . Consistent with these findings, HIF-1α-inducible genes, including the insulin-like growth factor binding protein (IGFBP3) and GLUT1, were up-regulated following nickel exposure (Figure 1) (Minet et al. 2001) .
In addition to the metal-specific effects, we examined the effect of arsenic dose on gene expression. The lower-dose arsenic exposure (5 µM) modified expression of a wide variety of genes representing a diverse range of protein classes such as transcription factors, inflammatory cytokines, kinases, and DNA repair proteins, as shown previously in human fibroblasts (Yih et al. 2002) and keratinocytes (Bae et al. 2002) . The literature supports the observed induction of heme oxygenase (HO1) (Menzel et al. 1998; Taketani et al. 1989; Yih et al. 2002) and the transcription factor junD (junD) (Liu et al. 2001 ). In addition, the immunoblot in Figure 3 confirmed that the HIF-1α gene expression changes were correlated with higher protein levels. We have also demonstrated dose-dependent increases in HIF-1α protein and mRNA levels in vascular smooth muscle cells (data not shown), suggesting that these effects of low-level arsenic are not confined to a single cell type. Further investigation will be needed to determine the downstream consequences of increases in levels HIF-1α and the other 11 transcription factors induced in response to 5-µM arsenic exposure. Arsenic exposure has also been associated with increased expression of the inflammatory cytokines, interleukin (IL)-6 and IL-8 via a mechanism that may also involve MAP kinase signaling pathways, as well as induction of other cytokines such as IL-12B, IL-7, and IL-2 (Wu et al. 1999 ).
The decreased expression of genes involved in DNA damage recognition and repair support the hypothesis that arsenic exposure may decrease the ability of exposed cells to recognize and repair DNA damage, potentially contributing to its carcinogenic and co-carcinogenic activity (Abernathy et al. 1999; Hartwig et al. 1997; Hartwig 1998; Rossman et al. 2001; Vogt and Rossman 2001) . For example, the following DNA repair genes were altered after arsenic treatment: Xeroderma pigmentosum group D-complementing protein (XPD, DNA excision repair protein ERCC2), Xeroderma pigmentosum group C-complementing protein (XPC), AP endonuclease 1 (APE1), DNA ligase-1 (DNL1), DNA polymerase delta catalytic subunit (DPD), DNA topoisomerase II alpha (TOP2A), DNA damage-inducible protein GADD45 (Chen et al. 2000; Liu et al. 2001 replication licensing factors 2 and 7 (MCM2, MCM7), proliferating cyclic nuclear antigen (PCNA), O 6 -methylguanine-DNA methyltransferase (MGMT), replication factor C large and 40-kDa subunits (RFC, RFC40), and uracil-DNA glycosylase precursor (UNG1). Other studies in our laboratory using human lymphocytes from an epidemiologic study have demonstrated a dose-dependent correlation between decreased expression of nucleotide excision repair genes and chronic exposure to arsenic in the drinking water (Andrew et al. 2003) . Surprisingly, increasing the dose of arsenic to 50 µM did not simply increase the magnitude of the change in the same set of genes or add additional genes. Rather, we observed a striking shift in the gene response profile between the lower and the higher dose. Exposure to 50 µM arsenic for 4 hr resulted in increased rather than decreased expression of nearly all genes that were modified, including many genes that prepare cells to deal with adverse conditions. Consistent with the concept of highdose arsenic acting as a heat-shock mimetic, 50 µM arsenic induced a variety of heatshock proteins [HSP-40, HSP-71, HSP-70 (Liu et al. 2001) , HSP-60 (Liu et al. 2001) , HSP90A, ]. Many of the other genes induced in response to higher doses of arsenic are involved in stress response pathways. Higher doses of arsenic increase levels of jun kinases (JNKs), possibly via mitogen-activated protein kinase kinases, such as MAPKK3, and also activate MAP kinases such as extracellular signal regulated kinase (ERK3) (Cavigelli et al. 1996; Liu et al. 1996; Porter et al. 1999; Samet et al. 1998; Wu et al. 1999) . Comparison between the microarray and kinase assay results shown in Figure 4 indicates a correlation between protein and gene-level changes in response to arsenic exposure for all genes that were examined in both studies: ERK3, ribosomal S6 kinase 1 (RSK1), cAMP-dependent protein kinase alpha-catalytic subunit (PKACα), and protein kinase B (PKB/akt1). This correlation between gene-and protein-level changes was also seen for PKB/akt following chromium treatment. Further investigation is necessary to determine how the observed changes in kinase expression levels affect signal transduction pathways. These experiments were performed in the BEAS-2B human bronchial epithelial cell line as well as primary pSMC, indicating that the observed changes are universal rather than cell-type or cell-line specific.
This study demonstrates the feasibility of using gene expression profiling to understand toxin-induced biological responses.
Overall, the number of genes modified in response to metal exposures was relatively small. Although a few genes were modified in response to more than one metal, each metal largely altered expression of a unique set of genes. The profile of genes induced by high-dose arsenic exposure clearly indicated a stress response, whereas the other nonovertly toxic doses of metals led to more subtle modification of cell signaling pathways. Future work will focus on using these data to explore basic mechanisms of metal toxicity and to generate new hypotheses. We invite other researchers to consider our data (Table 1 ) from the perspective of their own specialized areas of expertise. These metal response patterns may shed new light on the mechanisms of toxic metal-induced human diseases and may also be useful for development of molecular biomarkers of exposure and/or effect in mechanistic, epidemiologic, and risk assessment studies.
